Revelation Biosciences Inc. (NASDAQ: REVB), a clinical-stage life sciences company, has announced its financial results for the three and six months ended June 30, 2025. The company reported a net cash usage of $4.7 million for operating activities in the three months ending June 30, 2025, compared to $5.3 million in the same period in 2024. The net loss for this period was $2.4 million, a significant reduction from the $8.4 million net loss reported for the same period in 2024. For the six months ending June 30, 2025, Revelation reported a net loss of $4.5 million, compared to $11.1 million in the same period in 2024. As of June 30, 2025, the company had $5.2 million in cash and cash equivalents, down from $6.5 million as of December 31, 2024. This decrease was primarily due to cash used for operating activities. Revelation Biosciences completed the dosing of patients in the PRIME Phase 1b Clinical Study of Gemini in chronic kidney disease (CKD) patients and received gross proceeds of $4 million from a public offering in May 2025. The company believes its current cash and cash equivalents are sufficient to fund operations through December 2025. CEO James Rolke stated that the company plans to announce data from the Phase 1b study later this quarter and engage with the FDA to advance the clinical development of Gemini.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250808662780) on August 08, 2025, and is solely responsible for the information contained therein.
Comments